Ashley Li

Ashley Li

Auto-generated profile, based on publicly available information

Ashley Li

Department of Urology, University of Rochester Medical Center, Rochester, NY

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 April 2025 in The American Journal of Surgery
Verified
Journal Article
Closed access
ALAshley Li
Ashley Li
ZCZijing Cheng
Zijing Cheng
THTrevor C. Hunt
Trevor C. Hunt
STSimone Thavaseelan
Simone Thavaseelan
MCMadeline Cancian
Madeline Cancian
KMKamil Malshy
Kamil Malshy

14 September 2025 in Clinical Genitourinary Cancer
Verified
Journal Article
Closed access
MSMatthew Steidle
Matthew Steidle
KMKamil Malshy
Kamil Malshy
THTrevor C. Hunt
Trevor C. Hunt
ZCZijing Cheng
Zijing Cheng
ALAshley Li
Ashley Li
JBJathin Bandari
Jathin Bandari

1 December 2025 in JU Open Plus
Verified
Journal Article
Open access
VSVictor Sandoval
Victor Sandoval
EEElizabeth Ellis
Elizabeth Ellis
ALAshley Li
Ashley Li
TOThomas Osinski
Thomas Osinski
CFChangyong Feng
Changyong Feng
WTWilliam Tabayoyong
William Tabayoyong
Purpose: Currently, there is no clear consensus for long follow-up schedule after partial nephrectomy (PN) for T1 renal cell carcinoma (RCC) after more than 5 years. It is reasonable to stratify follow-up schedule based on tumor stage and histopathologic subtype. Here, we evaluated the time to recurrence and oncological outcomes during follow-up for T1 RCC categorized on histopathologic subtype at our institution to determine the optimal surveillance schedule after surgery. Material and Methods: We performed a retrospective analysis of PNs from 1997 to 2018 at the University of Rochester. The primary outcomes included time to recurrence; secondary outcomes were time to death (regardless of cause) and death from metastatic RCC. Demographic and clinical information were collected. Kaplan-Meier analysis was used to estimate the survival of each primary outcome in each histologic group. Cox proportional hazards model was used to study the association between the outcome and clinical stage, adjusting for the effects of age at surgery, recurrence rate, time to recurrence, age at recurrence, histopathology subtype, and margin status. Outcomes for those with clear cell (ccRCC), papillary, and chromophobe (chRCC) histopathologic subtypes were analyzed separately. Results: We identified 850 PNs at our institution with 537 patients having pT1 RCC on final pathology. The mean follow-up time was 63.5 months (maximum follow-up 136 months). A total of 28 patient had a recurrence. The median time to recurrence was 49 (1-3 IQR 28-65) months. Of the 28 patients who had recurrence, 7 patients (25%) had a recurrence after 5 years. For those patients who had recurrence after 5 years, the mean time to recurrence was 93.43 months (7.78 years). Significant differences were found in age at surgery, length of follow-up, recurrence rate, mortality rate, and cancer specific mortality between RCC subtypes and stage. Overall, recurrence for T1a tumors was 3% and for T1b tumors was 10%. Recurrence was associated with death (hazard risk 4.42, IC 95% [1.58-12.32], P = .0045). The presence of positive margins was not associated with recurrence or survival. Although there were significant differences in recurrence-free survival and overall survival for T1a vs T1b RCCs, these differences were not found between RCC histologic subtypes. Conclusions: From our retrospective data for T1 RCC tumors after PN, most recurrences occurred in patients with stage T1b cancer more than 3 years from the date of surgery. Overall survival and cancer-specific survival is excellent for those presenting for T1 RCC. Most mortality in this population is not caused by RCC; thus, it may be beneficial to have less frequent but longer surveillance for those presenting with sporadic T1 RCC.

2 December 2024 in World Journal of Urology
Verified
Journal Article
Closed access
PDF file
TCTimothy Campbell
Timothy Campbell
THTrevor C. Hunt
Trevor C. Hunt
ALAshley Li
Ashley Li
ZCZijing Cheng
Zijing Cheng
KMKamil Malshy
Kamil Malshy
JBJathin Bandari
Jathin Bandari

1 August 2025 in JU Open Plus
Verified
Journal Article
Open access
ALAshley Li
Ashley Li
ZCZijing Cheng
Zijing Cheng
THTrevor C. Hunt
Trevor C. Hunt
TCTimothy Campbell
Timothy Campbell
KMKamil Malshy
Kamil Malshy
KDKaren M Doersch
Karen M Doersch
Purpose: Although most trial design features can be borrowed from oncological trials, benign urology clinical trial design has not been well described. The purpose of this study was to compare serious adverse events (SAEs) and other study characteristics of benign vs malignant lower urinary tract clinical trials to understand safety and tolerability metrics as they apply to clinical trials of benign diseases. Methods: A search was performed on ClinicalTrials.gov for phase 1 benign lower urinary tract and bladder cancer studies from 2000 to 2024. The primary end point was SAE rates. Secondary endpoints were adverse event (AE) rates, all-cause mortality, and AEs requiring therapy termination. Results: A total of 52 clinical trials were included: 18 in the benign group and 34 in the malignant group. The malignant group had significantly higher number of SAEs and AEs. At the subject-level analysis, 284/987 subjects (28.77%) in the malignant group experienced a SAE compared with 16/554 subjects (2.89%) in the benign group (P < .001). AEs occurred in 818 subjects (82.88%) in the malignant trials and 222 subjects (40.07%) in the benign trials (P < .001). Despite these dissimilarities, there was no significant difference in the rate of AEs requiring therapy termination. Conclusions: There are significantly higher rates of SAE, AE, and mortality in malignant bladder phase 1 trials, but no difference in therapy termination in comparison with benign trials. More specifics in AE severity, reasons for therapy discontinuation, and study dropout need to be reported to guide future benign urology clinical trials.

1 February 2026 in JU Open Plus
Verified
Journal Article
Open access
ALAshley Li
Ashley Li
KMKamil Malshy
Kamil Malshy
MSMatthew Steidle
Matthew Steidle
ZCZijing Cheng
Zijing Cheng
YJYusheng Jia
Yusheng Jia
JBJathin Bandari
Jathin Bandari
Background: Recent studies have shown growth in the number of female residents and fellows in urology, a field that has historically been male dominated. Yet, the impact on subspecialty fellowships has not been well described. Objective: To analyze trends in female representation across American Urological Association (AUA) fellowship subspecialties. Methods: Fellowship match data (2014-2025) for Society of Urological Oncology (SUO), Endourological Society (EUS), American Society of Andrology (ASA), Society of Genitourinary Reconstructive Surgeons (GURS), and Society of Pediatric Urology (SPU) were analyzed. The primary analysis assessed trends in female-matched fellowship slots. Secondary analyses examined trends in female applicants, their proportion among matched applicants, and their distribution across all matched slots. Spearman correlation (ρ) measured monotonic trends. Results: Of the 2531 applicants, 437 (17.2%) were female, increasing from 13 in 2014 to 53 in 2024 (ρ = 0.92; P < .001). Overall, 358 (81.9%) women matched, with a significant rise from 9 in 2014 to 49 in 2024 (ρ = 0.84; P = .001). This increase was driven by SUO (ρ = 0.78; P = .003), EUS (ρ = 0.76; P = .004), and GURS (ρ = 0.67; P = .017), while SPU showed a nonsignificant decline (ρ = −0.58; P = .061). The proportion of women among matched applicants rose from 11.4% in 2014 to 30.6% in 2024, with SUO showing a significant increase (ρ = 0.73; P = .007). Within the matched female cohort, SPU proportions declined sharply from 52.2% in 2016 to 18.4% in 2024 (ρ = −0.9; P < .001). Conclusion: Female-matched fellowship slots significantly increased, driven by EUS, SUO, and GURS. SPU demonstrated a decline, whereas ASA showed no significant changes.